Essential Thrombocythemia.
暂无分享,去创建一个
[1] M. Cazzola,et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.
[2] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[3] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[4] A. Tefferi,et al. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.
[5] S. Iida,et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. , 2009, Blood.
[6] W. Vainchenker,et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. , 2009, Blood.
[7] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[8] W. Vainchenker,et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition , 2008, Leukemia.
[9] M. Ratajczak,et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. , 2002, Experimental hematology.
[10] R. Skoda,et al. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia , 1998, Nature Genetics.